Table 2

Guidelines and recommendations with treatment recommendations with AMR* considerations

VariableGuidelines
(N=78†)
Total no of recommendations (N=1198)No of recommendations with AMR consideration (N=808)Proportion of recommendations with AMR consideration (95% CI)
Continent
 International‡1193720.77 (0.67 to 0.85)
 North America295033210.64 (0.59 to 0.68)
 South America12670.27 (0.12 to 0.48)
 Europe274293340.78 (0.74 to 0.82)
 Africa12480.33 (0.16 to 0.55)
 Asia8119650.55 (0.45 to 0.64)
 Oceania1410.25 (0.01 to 0.78)
Publication year
 2007347340.72 (0.57 to 0.84)
 20082441.00 (0.40 to 1.00)
 20096175920.53 (0.45 to 0.60)
 2010345300.67 (0.51 to 0.80)
 2011877640.83 (0.72 to 0.90)
 201210144960.67 (0.58 to 0.74)
 2013712130.77 (0.68 to 0.84)
 20145167880.53 (0.45 to 0.60)
 2015737350.95 (0.80 to 0.99)
 2016108330.64 (0.53 to 0.74)
 20176129940.73 (0.64 to 0.80)
 2018549450.92 (0.80 to 0.97)
 20196120800.67 (0.57 to 0.75)
  • *AMR, antibiotic resistance.

  • †4/78 guidelines did not have recommendations that considered resistance.

  • ‡International, WHO.

  • AMR, antimicrobial resistance.